Start with the vertical axis
Imagine opening a paper and seeing two graphs for a fictional peptide. As the concentration rises, the line on the left falls. The one on the right climbs. Both captions name the same receptor. Which line tells you the peptide is doing something? Both can. Read the vertical axes and the apparent contradiction disappears.
The falling line could track how much of a labeled reference molecule, called a tracer, remains bound to the receptor. The rising line could track how much cyclic AMP (cAMP) accumulates inside cells. The first experiment follows a competitor’s effect on tracer binding. The second follows a cellular response associated with receptor activation.
Sources: Auld et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2018): Receptor Binding Assays for HTS and Drug Discovery · Sum et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2019): Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead Optimization
What falls in a competition binding curve?
A ligand is a molecule that binds a receptor. In a typical competition binding experiment, a labeled ligand provides the signal the instrument can see. As more of an unlabeled peptide is present, less tracer may remain bound. When the vertical axis is labeled “percent tracer bound,” a lower reading means the instrument detected less bound tracer. If the authors plot percent displacement instead, the same observations produce an upward curve.
The midpoint may be reported as an IC50, the competitor concentration that cuts specific tracer binding by half. That value depends in part on how much tracer is present and how tightly the tracer binds. An affinity estimate called Ki accounts for those factors under the assumptions of the competition model. If a paper reports Kd instead, check which ligand it describes. In a saturation binding experiment, Kd commonly describes the affinity of the labeled ligand itself.
What rises in a functional assay?
For the GLP-1 receptor, one common readout is cAMP, a molecule cells use to relay signals internally. If cAMP rises in a receptor-dependent assay, the researchers have evidence that the ligand activated the pathway leading to that signal. The functional EC50 is the concentration associated with half of the ligand’s fitted response range for that particular readout. The number describes a response in the assay system, so you need the endpoint and the model alongside it.
Return to our fictional peptide. Suppose it displaces the tracer but the cAMP curve stays flat. The first result supports binding under the conditions studied. The second means the assay detected no increase in cAMP in that comparison. A ligand that occupies the receptor and blocks another ligand’s response would be an antagonist. To make that claim here, look for a separate functional comparison that actually tests for blockade.
Sources: Auld et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2018): Receptor Binding Assays for HTS and Drug Discovery · Sum et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2019): Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead Optimization
A GLP-1 receptor study where the distinction matters
Figure 4 in a 2011 paper by Coopman and colleagues brings the two measurements together. The team compared the usual human GLP-1 receptor with altered versions expressed in HEK293 cells. They measured competition with a labeled exendin tracer in membrane preparations and measured GLP-1–stimulated cAMP in intact cells.
For several receptor variants, the loss in GLP-1’s potency for producing cAMP was larger than the loss in its binding affinity. One variant still showed measurable GLP-1 binding but gave essentially no cAMP response to GLP-1. The amount of receptor expressed varied among the constructs, and the binding and signaling panels used different preparations and forms of GLP-1. Several authors worked for AstraZeneca, which also provided financial support for the study.
Willard and colleagues reported a related contrast in 2020. At GLP-1R, tirzepatide had about fivefold weaker affinity than native GLP-1 in their competition assay and about twentyfold lower cAMP potency in their engineered-cell comparison. Each fold difference has its own reference measurement. The paper discloses that several authors worked for Eli Lilly and that some academic authors received Lilly research support.
Sources: Coopman et al., Molecular Endocrinology (2011): Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor · Willard et al., JCI Insight (2020): Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Three details to check before comparing panels
Write one line for each experiment in your notes. If the two lines name different models, reference ligands, or ways of measuring the result, carry those details into your summary.
Try the same exercise with a figure whose caption calls a compound “potent.” A steep-looking curve or a small concentration value can make that word feel self-explanatory. Before you repeat it, finish the sentence. Potent at displacing which tracer? Potent at producing which response? Add the reference compound if the authors used one. A few extra words turn a broad impression into a claim another reader can check.
- Name the signal. A binding panel might show tracer remaining. A signaling panel might show cAMP relative to a reference response.
- Check what is being compared. A membrane preparation and an intact cell give the receptor different surroundings. Even the amount of receptor expressed can change the functional curve. With a receptor reserve, the measured response can reach its maximum while some receptors are still unoccupied.
- Keep the parameters attached to their assays. A Ki describes affinity under a binding model. An EC50 describes the midpoint of a measured response. Preserve those labels even when both values use the same units.
Sources: Auld et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2018): Receptor Binding Assays for HTS and Drug Discovery · Sum et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2019): Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead Optimization · Coopman et al., Molecular Endocrinology (2011): Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor
Frequently asked questions
Why did Coopman’s team use an antagonist as a binding tracer?
Labeled exendin 9–39 served as a detectable reference ligand. As GLP-1 competed with it, the team could measure how much tracer remained bound. The antagonist’s ability to bind is what made that comparison possible.
Sources: Coopman et al., Molecular Endocrinology (2011): Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor · Auld et al., Assay Guidance Manual, NCATS and Eli Lilly & Company (2018): Receptor Binding Assays for HTS and Drug Discovery
Did the two panels in the Coopman study use the same form of GLP-1?
The Figure 4 caption identifies GLP-1 7–36 amide in the competition panels and GLP-1 7–37 in the cAMP panel. When citing a result, use the form named for that panel. The authors also report a similar pattern of potency differences when they used the amidated form in the functional assay.
Does the twentyfold difference in the tirzepatide study describe binding?
It refers to cAMP potency at GLP-1R relative to native GLP-1 in the engineered-cell assay. The paper reports a separate, approximately fivefold difference in binding affinity from competition measurements.
Did Willard and colleagues see the same pattern at the GIP receptor?
At GIPR, they found tirzepatide and native GIP had comparable binding affinity and cAMP potency in the low-receptor-density comparison. Keep the receptor and the reference peptide with the result when moving between panels.
Sources
- Receptor Binding Assays for HTS and Drug DiscoveryAuld et al., Assay Guidance Manual, NCATS and Eli Lilly & Company · 2018
- Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead OptimizationSum et al., Assay Guidance Manual, NCATS and Eli Lilly & Company · 2019
- Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptorCoopman et al., Molecular Endocrinology · 2011 · DOI: 10.1210/me.2011-1160
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistWillard et al., JCI Insight · 2020 · DOI: 10.1172/jci.insight.140532
Published by EliteGen Research for research education. Studies describe their own materials and experimental conditions; they do not establish the identity, quality, or suitability of an EliteGen product. This article does not provide guidance for personal, human, or veterinary use.



